The U.S. Food and Drug Administration issued a Complete Response Letter to Merck & Co. for the company’s New Drug Application for gefapixant for refractory chronic cough or unexplained chronic cough.

Researchers at Massachusetts Institute of Technology (MIT) developed an artificial intelligence (AI) model able to detect asymptomatic Covid-19 cases by identifying differences in the sounds of coughs between healthy and infected people.

The wind howls and new-fallen leaves swirl around. There’s a sense of dread hanging in the air. Monsters are about, spreading terror across the land. The sound of coughing and gasping breath is coming up fast. A slow look over your shoulder reveals the sweaty, nightmare visage of Covid-19 – or does it?

The U.S. Centers for Disease Control and Prevention warned that Covid-19 could spread through airborne particles that can remain suspended in the air and travel beyond six feet.

Vernalis plc announces today that the US Food and Drug Administration issued a Complete Response Letter (CRL) regarding the New Drug Application for CCP-07.

Merck & Co. is acquiring Afferent Pharmaceuticals for an upfront cash payout of $500 million of stock and an additional $750 million based on various clinical and commercial milestones.